IRMD
IRADIMED CORPORATION
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Last price
88.59
▲ 1.91 (2.21%)
MARKET · —
Price
Open
86.83
Prev close
86.68
Day high
87.95
Day low
86.34
Volume
72.54K
Market cap
$1.12B
P/E (TTM)
49.08
52W range
67.84 – 107.90
Trailing performance
Returnvs SPY
1W
+1.04%
+2.4%
1M
-6.40%
-10.1%
3M
-5.71%
-8.8%
6M
-15.17%
-26.2%
YTD
-9.69%
-22.0%
1Y
+25.82%
+5.8%
3Y
+80.65%
+6.5%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$1.12B
Enterprise value$1.06B
Revenue (TTM)$86.34M
Gross profit$65.50M
EBITDA$29.18M
Net income$23.05M
EPS (TTM)$1.79
Free cash flow$16.20M
Total cash$59.08M
Total debt$0
Book value / share$7.96
Shares outstanding12.79M
Float8.33M
Short % of float8.08%
Dividend yield0.91%
Beta (5Y)0.91
Valuation & profitability ratios
Trailing P/E49.08
Forward P/E36.45
PEG ratio—
Price / sales—
Price / book11.04
EV / revenue12.33
EV / EBITDA36.47
Gross margin75.86%
Operating margin31.23%
Profit margin26.70%
Return on equity23.52%
Return on assets15.56%
Debt / equity—
Current ratio9.46
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $83.81M | $73.24M | $65.56M | $53.30M |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | $22.48M | $19.23M | $17.19M | $12.83M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | $22.48M | $19.23M | $17.19M | $12.83M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.44 | 0.46 | +4.6% |
| Mar 2026 | 0.45 | 0.49 | +10.1% |
| Dec 2025 | 0.48 | 0.54 | +12.5% |
| Sep 2025 | 0.46 | 0.47 | +3.3% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.55 | 2 | $23.20M | +9.4% |
| Next quarter | 0.62 | 2 | $25.60M | +12.8% |
| Current year | 2.09 | 2 | $91.20M | +8.8% |
| Next year | 2.41 | 2 | $101.00M | +10.8% |
Analyst targets & ownership
Mean target$118.00
High target$120.00
Low target$116.00
Implied upside33.19%
Analyst count2
ConsensusNONE
Strong buy / Buy0 / 2
Hold0
Sell / Strong sell0 / 0
Held by insiders35.19%
Held by institutions62.81%
Institutions holding312
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
-97.20K
Net selling
Buy transactions
1
5.80K shares
Sell transactions
15
103.00K shares
Net transactions
+16
Buys less sells
Sell : buy shares
17.8 : 1
Heavily one-sided
Insider-held shares
4.50M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jun 18, 26 | GLENN JOHN F Chief Financial Officer |
— | 5.80K | — | Direct |
| Jun 4, 26 | SCHAREN-GUIVEL HILDA FREDERIQUE Director |
SELL | 3.00K | $285.00K | Direct |
| Jun 1, 26 | SUSI ROGER E Chief Executive Officer |
SELL | 2.50K | $226.51K | Indirect |
| May 27, 26 | SUSI ROGER E Chief Executive Officer |
SELL | 7.50K | $691.04K | Indirect |
| May 19, 26 | SUSI ROGER E Chief Executive Officer |
SELL | 7.50K | $657.26K | Indirect |
| May 12, 26 | SUSI ROGER E Chief Executive Officer |
SELL | 7.50K | $631.34K | Indirect |
| May 5, 26 | SUSI ROGER E Chief Executive Officer |
SELL | 7.50K | $642.86K | Indirect |
| Apr 28, 26 | SUSI ROGER E Chief Executive Officer |
SELL | 7.50K | $657.71K | Indirect |
| Apr 21, 26 | SUSI ROGER E Chief Executive Officer |
SELL | 7.50K | $694.12K | Indirect |
| Apr 14, 26 | SUSI ROGER E Chief Executive Officer |
SELL | 7.50K | $697.19K | Indirect |
| Apr 7, 26 | SUSI ROGER E Chief Executive Officer |
SELL | 7.50K | $717.21K | Indirect |
| Mar 30, 26 | SUSI ROGER E Chief Executive Officer |
SELL | 7.50K | $712.61K | Indirect |
| Mar 24, 26 | SUSI ROGER E Chief Executive Officer |
SELL | 7.50K | $752.61K | Indirect |
| Mar 17, 26 | SUSI ROGER E Chief Executive Officer |
SELL | 7.50K | $762.97K | Indirect |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ALLEN MONTY K |
Director | 21.00K | Sale |
CHIPRIN JEFF |
Officer | 687 | Conversion of Exercise of derivative security |
GLENN JOHN F |
Chief Financial Officer | 11.94K | Conversion of Exercise of derivative security |
HAWKINS JAMES B |
Director | 29.65K | Conversion of Exercise of derivative security |
SCHAREN-GUIVEL HILDA FREDERIQUE |
Director | 5.60K | Sale |
SUSI ROGER E |
Chief Executive Officer | — | Sale |
VUOTO ANTHONY F |
Director | 17.18K | Conversion of Exercise of derivative security |
Moving averages & technicals
SMA 10
87.82
+0.88% from price
SMA 20
90.44
-2.86% from price
SMA 50
93.32
-5.86% from price
SMA 100
91.97
-3.67% from price
SMA 200
94.42
-6.95% from price
EMA 12
88.63
-0.04% from price
EMA 26
90.58
-2.19% from price
EMA 50
91.89
-3.58% from price
RSI (14)
40.2
Neutral
MACD (12,26,9)
-1.95
Hist -0.24
ATR (14)
2.56
2.91% of price
Realised vol 30D
31.0%
Annualised
Bollinger upper
96.31
20, 2σ
Bollinger lower
84.56
20, 2σ
50 / 200 cross
Death
93.32 vs 94.42
Trend bias
Below 200
-6.95%
Risk profile
Beta vs SPY
0.66
Less volatile than market
Correlation to SPY
0.27
Largely independent
Realised vol 30D
31.0%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-20.6%
Peak to trough
Max drawdown 5Y
-49.4%
Peak to trough
ATR 14
2.56
2.91% of price
Beta (reported)
0.91
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
10.00
Put-heavy session
Put / call open interest
0.48
Positioning, not flow
Max pain
75.00
-14.6% from spot
ATM implied vol
51.7%
Nearest strike to spot
Skew (10% OTM)
+7.2%
Puts bid over calls
Call volume
1
Contracts, this expiry
Put volume
10
Contracts, this expiry
Heaviest call OI
100.00
10 contracts
Heaviest put OI
80.00
10 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
IRadimed (IRMD) Q2 2026 Earnings Call Transcript
Motley Fool · 15d ago
How IRADIMED's Modest Q2 Beat and Reaffirmed 2026 Guidance Will Impact IRMD Investors
Simply Wall St. · 15d ago
Replacement Cycle Anchors IRadimed Corp.’s (IRMD) Long Term Growth
Insider Monkey · 15d ago
iRadimed Corp (IRMD) (Q2 2026) Earnings Call Highlights: Strong Demand for New 3,870 Pump ...
GuruFocus.com · 19d ago
IRadimed Corporation Q2 2026 Earnings Call Summary
Moby · 21d ago
iRadimed Q2 Earnings Call Highlights
MarketBeat · 22d ago
IRadimed Q2 Adjusted Earnings Fall, Revenue Rises; Issues Q3 Outlook, Reaffirms 2026 Guidance
MT Newswires · 22d ago
IRadimed: Q2 Earnings Snapshot
Associated Press · 22d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.